Zepbound 7.5 MG/0.5 ML pen 0.5ML
Ended Awarded
- Contract number
- SPE2DR26F6CTZ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,426
Award facts
- Contract value 100% obligated
- $9,426.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,426.06 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on November 4, 2025, with completion scheduled for November 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, holds significant federal contracting relationships as a critical vendor for military and veteran healthcare systems. The company's extensive portfolio of federal contracts demonstrates its capability to supply a wide range of pharmaceutical products, medical devices, and healthcare commodities across multiple therapeutic domains. As a child contract under the broader DLA Troop Support Medical IDC, this delivery order for Zepbound—a GLP-1 receptor agonist medication—supports the Defense Health Agency and other government healthcare systems' medical supply requirements through DLA's flexible and comprehensive contract vehicle.
Quick answers
Who was awarded contract SPE2DR26F6CTZ?
SPE2DR26F6CTZ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DR26F6CTZ worth?
The government has obligated $9,426 on SPE2DR26F6CTZ.
Is contract SPE2DR26F6CTZ an order under another contract?
Yes. SPE2DR26F6CTZ is a delivery order under SPE2DR25D2213, an indefinite delivery contract.
Was contract SPE2DR26F6CTZ competed?
The extent of competition for SPE2DR26F6CTZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award